SPPI - Spectrum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.95
-0.05 (-0.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close20.00
Open19.93
Bid19.04 x 1800
Ask20.30 x 1400
Day's Range19.49 - 20.04
52 Week Range6.50 - 23.50
Volume1,350,665
Avg. Volume1,642,052
Market Cap2.056B
Beta2.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-18
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...

  • Business Wire19 days ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRE24 days ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Business Wirelast month

    CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.

  • Business Wirelast month

    Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed results from ADVANCE, a Phase 3 trial of ROLONTIS, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. “These data expand our understanding of the clinical profile of eflapegrastim and help establish it as a possible supportive care treatment option for the multitude of patients undergoing chemotherapy,” said Lee Schwartzberg, M.D., FACP, lead investigator, professor of medicine and division chief, hematology oncology, University of Tennessee Health Science Center, and executive director, UT/West Cancer Center.

  • Business Wirelast month

    Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. A live webcast of Spectrum’s presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRElast month

    Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.

  • Business Wirelast month

    Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended March 31, 2018.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib. “We have been aggressively pursuing the potential of exon 20 mutations and treatment with poziotinib since the inception of our relationship with MD Anderson, but we’ve both only begun to scratch the surface of the science and poziotinib’s potential as a targeted treatment for various solid tumors,” said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher Scientific to leverage the Oncomine™ Dx Target Test as a companion diagnostic for Spectrum’s novel pan-HER inhibitor, poziotinib, which is in development for the ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that it has taken a number of actions designed to further enhance its corporate governance practices. On March 23, 2018, the board approved amendments to Spectrum’s bylaws and shareholder rights plan to establish proxy access rights, implement a majority voting standard and rescind the stockholder rights plan, commonly referred to as a poison pill. Additionally, the nominating and corporate governance committee has recommended one new candidate, Dr. Bernice Welles, to replace Dr. Rajesh Shrotriya and Dr. Luigi Lenaz, and will reduce the size of the board to eight members.

  • Business Wire2 months ago

    Company Profile for SPECTRUM PHARMACEUTICALS

    Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, May 3, 2018 ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer.” The publication appears in the April 23, 2018 online issue at https://www.nature.com/articles/s41591-018-0007-9 and will be published in a future print issue of Nature Medicine. “We are honored to have data from poziotinib published in this prestigious journal,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. For cancer patients that have exon 20 mutations, physicians have very few options.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

    Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors ...

  • ACCESSWIRE2 months ago

    Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients

    Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / April 11, 2018 / Spectrum Pharmaceuticals and Tandem Diabetes Care both exploded in Tuesday trading. Spectrum headed higher after announcing positive data from a phase 2 trial ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant Non-Small Cell Lung Cancer study are available, based on longer follow-up.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th

    Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the H.C.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Spectrum Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / U.S. markets had a topsy-turvy day as concerns of a potential trade war, a result of tariffs proposed by President Donald Trump, continue to worry investors. ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Spectrum Pharmaceuticals and Portola Pharmaceuticals were two of the most active biotech stocks in the market on Tuesday. Spectrum reported its fourth quarter ...

  • Business Wire3 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th

    Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Cowen and Company 38th Annual Health Care Conference being held at The Boston Marriott Copley Place in ...

  • Business Wire3 months ago

    Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update

    Spectrum Pharmaceuticals, Inc. , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results for the three-month period and year ended December 31, 2017.

  • ACCESSWIRE3 months ago

    Spectrum Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018 at 4:30 PM Eastern ...